SCHEMBL6038560

SCHEMBL6038560

COc1ccc(COc2nc(-c3cccc(N)c3)cnc2NS(=O)(=O)c2ccc(C)cc2)cc1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 1/20 0.58
CSF1R P07333 1/20 0.40
EDNRA P25101 5/20 0.39
KMO O15229 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
QPCT Q16769 1/20 0.38
QPCTL Q9NXS2 1/20 0.38
TP53 P04637 2/20 0.38
MAPT P10636 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
RAB9A P51151 1/20 0.38
PAX8 Q06710 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TSHR P16473 1/20 0.38
CD63 P08962 1/20 0.38
SYK P43405 1/20 0.38
PLAU P00749 1/20 0.37
TYRO3 Q06418 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038953 0.91 CCR4 (0.59) CCR4CSF1RKMOMEN1KMT2A
SCHEMBL6038535 0.90 CCR4 (0.65) CCR4CSF1REDNRAMEN1KMT2A
SCHEMBL6038583 0.89 CCR4 (0.60) CCR4EDNRAKMOMEN1KMT2A
SCHEMBL6038467 0.89 CCR4 (0.56) CCR4EDNRAKMOMEN1KMT2A
SCHEMBL6038593 0.85 CCR4 (0.48) CCR4MEN1KMT2AMAPTALDH1A1
SCHEMBL6038637 0.83 CCR4 (0.68) CCR4EDNRAMEN1KMT2ATP53
SCHEMBL6039115 0.82 CCR4 (0.53) CCR4
SCHEMBL6038499 0.81 CCR4 (0.82) CCR4EDNRA
SCHEMBL6038792 0.77 CCR4 (0.47) CCR4MEN1KMT2ATP53MAPT
SCHEMBL6038976 0.77 CCR4 (0.50) CCR4MEN1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 CCR4 1/4885CSF1R 354/4885EDNRA 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.